Hansa Biopharma: AMR study with a convincing primary endpoint result - Redeye

Imlifidase shows a superior ability reducing donor-specific antibodies (DSAs) in the phase 2 study involving 30 AMR patients compared with PE (plasma exchange). This is a smaller study and the graft function was assessed as a secondary endpoint where PE came out stronger. We look forward to the publication and a further assessment of Imlifidase performance among acute AMR (the study includes both acute and chronic AMR). Realistically Imlifidase is most appropriate in the acute setting.

Länk till analysen i sin helhet: https://www.redeye.se/research/967301/hansa-biopharma-amr-study-with-a-convincing-primary-endpoint-result?utm_source=finwire&utm_medium=RSS